Novel Therapies for Brain Cancer

This trial tests new treatments for individuals with recurrent or progressive atypical teratoid rhabdoid tumors (ATRT), a type of brain cancer. The study aims to evaluate the safety and effectiveness of a combination of two drugs: gemcitabine (a chemotherapy drug) and paxalisib (a potential new treatment). Participants will receive these drugs over a series of cycles to determine the optimal dosage and assess their impact on the tumor. The trial seeks individuals diagnosed with ATRT that has returned or worsened after previous treatments. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial requires a washout period (time without taking certain medications) for previous cancer treatments before you can join. If you're on corticosteroids, you need to be on a stable or decreasing dose for at least a week before enrolling. The protocol doesn't specify about other medications, so it's best to discuss with the trial team.

A previous study showed that combining gemcitabine and paxalisib could slow tumor growth and significantly extend survival time, with average survival increasing from 22 days to 82.5 days. This suggests it could effectively treat certain brain cancers.

Research on paxalisib alone has shown it to be generally safe. It has been studied in various cancer types and has received special recognition from the FDA for treating glioblastoma, a type of brain cancer, indicating its promise for rare conditions.

Gemcitabine is a well-known chemotherapy drug often used in cancer treatment. Its successful use in other cancers suggests it might be safe for brain cancer when combined with paxalisib.

Researchers are excited about the combination of gemcitabine and paxalisib for treating brain cancer because it targets the disease in a novel way. Unlike traditional treatments like surgery, radiation, and temozolomide, which primarily focus on removing or shrinking tumors, paxalisib inhibits a specific pathway called PI3K, which is crucial for cancer cell survival and growth. Combining this with gemcitabine, a chemotherapy drug known for its ability to prevent cancer cells from reproducing, could offer a more powerful one-two punch against the cancer. This innovative approach has the potential to improve outcomes for patients who have few options beyond the standard treatments.

Research has shown that combining gemcitabine and paxalisib may help treat aggressive brain tumors. In lab studies, this combination increased the average survival time from 22 days to 82.5 days. Participants in this trial will receive this combination therapy to evaluate its effectiveness. Paxalisib alone has also extended survival for patients with glioblastoma, a type of brain cancer, by several months. This suggests that paxalisib, especially when combined with gemcitabine, could be effective against certain brain cancers like ATRT (atypical teratoid/rhabdoid tumor). This combination works by slowing tumor growth and may improve patient outcomes.¹⁵⁶⁷⁸